TITLE

Review: Donepezil improves cognitive and functional outcomes in vascular cognitive impairment

AUTHOR(S)
Gill, Sudeep S.; Rocbon, Paula A.
PUB. DATE
September 2004
SOURCE
ACP Journal Club;Sep/Oct2004, Vol. 141 Issue 2, p39
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on placebo-controlled trials of donepezil in patients with vascular cognitive impairment or vascular or mixed dementia. Patients who received donepezil had greater improvements in cognitive function at 12 and 24 weeks than did patients who received placebo. It is clear, however, that Alzheimer disease (AD) and cerebrovascular disease frequently coexist in patients with dementia 2. Cholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, target this cholinergic deficit and have been shown to improve cognitive and functional measures in patients with AD.
ACCESSION #
14590724

 

Related Articles

  • Donepezil In Vascular Dementia. Goldsmith, David R.; Scott, Lesley J. // Drugs & Aging;2003, Vol. 20 Issue 15, p1127 

    Vascular dementia (VaD), caused by stroke or small vessel disease, is the second most common form of dementia after Alzheimer's disease (AD). Donepezil, an acetylcholinesterase inhibitor currently indicated for use in patients with mild to moderate AD, has recently been evaluated in...

  • Effects of Cholinesterase Inhibiting Sage (Salvia officinalis) on Mood, Anxiety and Performance on a Psychological Stressor Battery. Kennedy, David O.; Pace, Sonia; Haskell, Crystal; Okello, Edward J.; Milne, Anthea; Scholey, Andrew B. // Neuropsychopharmacology;Apr2006, Vol. 31 Issue 4, p845 

    Salvia officinalis (sage) has previously been shown both to possess in vitro cholinesterase inhibiting properties, and to enhance mnemonic performance and improve mood in healthy young participants. In this double-blind, placebo-controlled, crossover study, 30 healthy participants attended the...

  • Optimal Dosing of Galantamine in Patients with Mild or Moderate Alzheimer's Disease. Aronson, Stephen; Van Baelen, Bart; Kavanagh, Shane; Schwalen, Susanne // Drugs & Aging;2009, Vol. 26 Issue 3, p231 

    Background: Galantamine (hydrobromide), a reversible acetylcholinesterase inhibitor and allosteric nicotinic receptor modulator, slows cognitive and functional decline in mild to moderate dementia of the Alzheimer's type. Although several drugs are indicated for mild to moderate Alzheimer's...

  • Defining Treatment Response to Donepezil in AlzheimerÂ’s Disease: Responder Analysis of Patient-Level Data from Randomized, Placebo-Controlled Studies. Burns, Alistair; Yeates, Andrew; Akintade, Latif; del Valle, Megan; Zhang, Richard Y.; Schwam, Elias M.; Perdomo, Carlos A. // Drugs & Aging;2008, Vol. 25 Issue 8, p707 

    BACKGROUND: Defining treatment success in progressive diseases, such as Alzheimer’s disease (AD), can be challenging. OBJECTIVE: To explore the impact of employing different criteria to define a treatment ‘responder’ using analyses of patient-level data from randomized,...

  • Cholinesterase Inhibitors as Adjunctive Therapy in Patients with Schizophrenia and Schizoaffective Disorder. Ribeiz, Salma R. I.; Bassitt, Débora P.; Arrais, Jony A.; Avila, Renata; Steffens, David C.; Bottino, Cássio M. C. // CNS Drugs;2010, Vol. 24 Issue 4, p303 

    Background: Cognitive deficits have been described in patients with schizophrenia from the first descriptions of dementia praecox to current concepts of cognitive dysmetria. Nevertheless, little is known about how to deal with them. In Alzheimer disease, cholinergic deficit is found and...

  • Cerebral Acetylcholinesterase Imaging: Development of the Radioprobes. Kikuchi, Tatsuya; Okamura, Toshimitsu; Fukushi, Kiyoshi; Takahashi, Kazuhiro; Toyohara, Jun; Okada, Maki; Zhang, Ming-Rong; Irie, Toshiaki // Current Topics in Medicinal Chemistry;Sep2007, Vol. 7 Issue 18, p1790 

    Cerebral acetylcholinesterase (AChE) imaging is not only useful for diagnosis of dementia disorders but also for therapeutic monitoring of the effects of cholinesterase (ChE) inhibitors and for decision of the appropriate clinical dosage of newly developed ChE inhibitors. Several ChE inhibitors...

  • Advances in the Structural Modification of Huperzine A. YI Jia-bao; YAN Jie; LI Xu-ming // Natural Product Research & Development;Dec2009, Vol. 21 Issue 6, p1080 

    Huperzine A was a powerful selective reversible inhibitor of acetylcholinesterase and a promising drug for Alzheimer's Disease. The property, structure, and structure activity relationship of huperzine A were summarized. The advances in the structural modification of huperzine A were reviewed...

  • Acetylcholinesterase inhibitors: modest improvements in AD.  // PharmacoEconomics & Outcomes News;9/24/2005, Issue 487, p13 

    Discusses research being done on the effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Reference to a study conducted by R. Raschetti, M. Maggini, G.C. Sorrentino, N. Martini, B. Caffari and N. Vanacore, published in the July 2005 issue of the "European Journal of...

  • Acetylcholinesterase inhibitors: modest improvements in AD.  // PharmacoEconomics & Outcomes News;9/24/2005, Issue 487, p13 

    Discusses research being done on the effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Reference to a study conducted by R. Raschetti, M. Maggini, G.C. Sorrentino, N. Martini, B. Caffari and N. Vanacore, published in the July 2005 issue of the "European Journal of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics